Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- Sigma-1 Agonist; Uncompetitive N-methyl-D-aspartate Receptor Antagonist FDA class
- Tested for
- Mitochondrial Disease
- Main trialPhase 1
- “A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects”In the company’s words, NCT04643249 on ClinicalTrials.gov
Other drugs for Mitochondrial Disease
- NomlabofuspLarimar Therapeutics, Inc. · Phase 3
- OmaveloxoloneBiogen · Phase 3
- SepofarsenLaboratoires Thea · Phase 3
- VatiquinonePTC Therapeutics · Phase 3
- SonlicromanolKhondrion BV · Phase 3
- DichloroacetateSaol Therapeutics Inc · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 17 Dec 2020 | Drug-drug Interaction Study of KL1333 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026